Major Shift in U.S. Drug Policy
The United States has taken a significant step toward changing how marijuana is classified under federal law, with the Trump administration moving to reclassify it as a less dangerous substance.
Under the proposal, certain cannabis products would be moved from Schedule I to Schedule III under the Controlled Substances Act, placing them in a category with drugs considered to have accepted medical uses but lower abuse potential.
What the Change Actually Means
Despite the headlines, marijuana would still remain illegal at the federal level. The change does not legalize recreational use nationwide, nor does it automatically erase past convictions.
Instead, it mainly affects regulation, research access, and taxation, making it easier for scientists to study cannabis and for licensed businesses to operate under federal tax rules.
Growing Debate Over Health and Safety
The policy shift comes at a time when cannabis use is widespread across the United States, with most states already allowing it in some form for medical or recreational use.
While many see the change as long overdue, health experts continue to debate the long-term effects of regular cannabis use, especially with stronger modern THC products.
Medical Concerns Raised by Specialists
Dr Jeremy London, a cardiovascular surgeon with over 25 years of experience, has raised concerns about the effects of smoking marijuana on heart health.
He argues that regular cannabis smoking may increase the risk of coronary disease and heart attack by around 1.3 to 2 times compared to non-users.
What Doctors Say They See in Patients
According to Dr London, some patients who regularly smoked marijuana showed severe arterial blockages requiring bypass surgery, even in cases where they had never smoked cigarettes.
He also noted that lungs of long-term smokers often show significant damage, describing them as appearing heavily discolored during surgery.
Cannabis and Emerging Health Research
Recent studies have also linked heavy cannabis use to potential risks including mental health issues, dependency, and a rare condition called cannabinoid hyperemesis syndrome, which causes severe vomiting episodes.
However, researchers stress that the full picture is still developing due to limited long-term data.
Why Research Has Been Limited Until Now
Because marijuana was previously classified as a Schedule I drug, scientific research was heavily restricted in the United States.
The new classification could allow more detailed studies into both the benefits and risks of cannabis use, especially as products become more potent and widely available.
A Policy Shift Still Under Debate
Supporters of the change say it is a step toward evidence-based policy and improved medical access. Critics argue it may downplay potential health risks and create a false sense of safety among users.
Experts emphasize that the key issue is not simple legalization, but better understanding of how cannabis affects the body.
